Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Capital Expenditures (2021 - 2023)

Historic Capital Expenditures for Aligos Therapeutics (ALGS) over the last 3 years, with Q1 2023 value amounting to $7000.0.

  • Aligos Therapeutics' Capital Expenditures fell 9864.08% to $7000.0 in Q1 2023 from the same period last year, while for Mar 2023 it was $435000.0, marking a year-over-year decrease of 6045.45%. This contributed to the annual value of $130000.0 for FY2024, which is 58421.05% up from last year.
  • Per Aligos Therapeutics' latest filing, its Capital Expenditures stood at $7000.0 for Q1 2023, which was down 9864.08% from $91000.0 recorded in Q4 2022.
  • In the past 5 years, Aligos Therapeutics' Capital Expenditures ranged from a high of $515000.0 in Q1 2022 and a low of $3000.0 during Q3 2022
  • In the last 3 years, Aligos Therapeutics' Capital Expenditures had a median value of $152000.0 in 2021 and averaged $204666.7.
  • Its Capital Expenditures has fluctuated over the past 5 years, first soared by 11973.68% in 2022, then tumbled by 9864.08% in 2023.
  • Over the past 3 years, Aligos Therapeutics' Capital Expenditures (Quarter) stood at $336000.0 in 2021, then plummeted by 72.92% to $91000.0 in 2022, then crashed by 92.31% to $7000.0 in 2023.
  • Its Capital Expenditures stands at $7000.0 for Q1 2023, versus $91000.0 for Q4 2022 and $3000.0 for Q3 2022.